Modality
Nanobody
MOA
CD3xCD20
Target
FGFR
Pathway
mTOR
Ewing Sarcoma
Development Pipeline
Preclinical
~Feb 2018
→ ~May 2019
Phase 1
Aug 2019
→ Sep 2029
Phase 1Current
NCT06311738
1,468 pts·Ewing Sarcoma
2019-08→2029-09·Terminated
1,468 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-193.5y awayPh2 Data· Ewing Sarcoma
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Termina…
Catalysts
Ph2 Data
2029-09-19 · 3.5y away
Ewing Sarcoma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06311738 | Phase 1/2 | Ewing Sarcoma | Terminated | 1468 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA |